Cargando…
Preventable adverse drug events: Descriptive epidemiology
AIM: Our objective was to identify preventable adverse drug events and factors contributing to their development. METHODS: We performed a retrospective chart review combining data from three prospective multicentre observational studies that assessed emergency department patients for adverse drug ev...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015751/ https://www.ncbi.nlm.nih.gov/pubmed/31633827 http://dx.doi.org/10.1111/bcp.14139 |
_version_ | 1783496856448270336 |
---|---|
author | Woo, Stephanie A. Cragg, Amber Wickham, Maeve E. Villanyi, Diane Scheuermeyer, Frank Hau, Jeffrey P. Hohl, Corinne M. |
author_facet | Woo, Stephanie A. Cragg, Amber Wickham, Maeve E. Villanyi, Diane Scheuermeyer, Frank Hau, Jeffrey P. Hohl, Corinne M. |
author_sort | Woo, Stephanie A. |
collection | PubMed |
description | AIM: Our objective was to identify preventable adverse drug events and factors contributing to their development. METHODS: We performed a retrospective chart review combining data from three prospective multicentre observational studies that assessed emergency department patients for adverse drug events. A clinical pharmacist and physician independently reviewed the charts, extracted data and rated the preventability of each adverse drug event. A third reviewer adjudicated all discordant or uncertain cases. We calculated the proportion of adverse drug events that were deemed preventable, performed multivariable logistic regression to explore the characteristics of patients with preventable events, and identified contributing factors. RESULTS: We reviewed the records of 1 356 adverse drug events in 1 234 patients. Raters considered 869 (64.1%) of adverse drug events probably or definitely preventable. Patients with mental health diagnoses (OR 1.8; 95% CI 1.3–2.5) and diabetes (OR 1.7; 95% CI 1.2–2.4) were more likely to present with preventable events. The medications most commonly implicated in preventable events were warfarin (9.4%), hydrochlorothiazide (4.5%), furosemide (4.0%), insulin (3.9%) and acetylsalicylic acid (2.7%). Common contributing factors included inadequate patient instructions, monitoring and follow‐up, and reassessments after medication changes had been made. CONCLUSIONS: Our study suggests that patients with mental health conditions and diabetes require close monitoring. Efforts to address the identified contributing factors are needed. |
format | Online Article Text |
id | pubmed-7015751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70157512020-03-06 Preventable adverse drug events: Descriptive epidemiology Woo, Stephanie A. Cragg, Amber Wickham, Maeve E. Villanyi, Diane Scheuermeyer, Frank Hau, Jeffrey P. Hohl, Corinne M. Br J Clin Pharmacol Original Articles AIM: Our objective was to identify preventable adverse drug events and factors contributing to their development. METHODS: We performed a retrospective chart review combining data from three prospective multicentre observational studies that assessed emergency department patients for adverse drug events. A clinical pharmacist and physician independently reviewed the charts, extracted data and rated the preventability of each adverse drug event. A third reviewer adjudicated all discordant or uncertain cases. We calculated the proportion of adverse drug events that were deemed preventable, performed multivariable logistic regression to explore the characteristics of patients with preventable events, and identified contributing factors. RESULTS: We reviewed the records of 1 356 adverse drug events in 1 234 patients. Raters considered 869 (64.1%) of adverse drug events probably or definitely preventable. Patients with mental health diagnoses (OR 1.8; 95% CI 1.3–2.5) and diabetes (OR 1.7; 95% CI 1.2–2.4) were more likely to present with preventable events. The medications most commonly implicated in preventable events were warfarin (9.4%), hydrochlorothiazide (4.5%), furosemide (4.0%), insulin (3.9%) and acetylsalicylic acid (2.7%). Common contributing factors included inadequate patient instructions, monitoring and follow‐up, and reassessments after medication changes had been made. CONCLUSIONS: Our study suggests that patients with mental health conditions and diabetes require close monitoring. Efforts to address the identified contributing factors are needed. John Wiley and Sons Inc. 2020-01-10 2020-02 /pmc/articles/PMC7015751/ /pubmed/31633827 http://dx.doi.org/10.1111/bcp.14139 Text en © 2019 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Woo, Stephanie A. Cragg, Amber Wickham, Maeve E. Villanyi, Diane Scheuermeyer, Frank Hau, Jeffrey P. Hohl, Corinne M. Preventable adverse drug events: Descriptive epidemiology |
title | Preventable adverse drug events: Descriptive epidemiology |
title_full | Preventable adverse drug events: Descriptive epidemiology |
title_fullStr | Preventable adverse drug events: Descriptive epidemiology |
title_full_unstemmed | Preventable adverse drug events: Descriptive epidemiology |
title_short | Preventable adverse drug events: Descriptive epidemiology |
title_sort | preventable adverse drug events: descriptive epidemiology |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015751/ https://www.ncbi.nlm.nih.gov/pubmed/31633827 http://dx.doi.org/10.1111/bcp.14139 |
work_keys_str_mv | AT woostephaniea preventableadversedrugeventsdescriptiveepidemiology AT craggamber preventableadversedrugeventsdescriptiveepidemiology AT wickhammaevee preventableadversedrugeventsdescriptiveepidemiology AT villanyidiane preventableadversedrugeventsdescriptiveepidemiology AT scheuermeyerfrank preventableadversedrugeventsdescriptiveepidemiology AT haujeffreyp preventableadversedrugeventsdescriptiveepidemiology AT hohlcorinnem preventableadversedrugeventsdescriptiveepidemiology |